Magnetic resonance imaging of the substantia nigra in Parkinson's disease

Movement Disorders

Volumn 27, Issue 7, 2012, Pages 822-830

  Lehéricy, Stéphane ^a,b,c,d,e   Sharman, Michael A ^a,b,c,d,e   Santos, Clarisse Longo Dos ^a,b,c,d,e,f   Paquin, Raphaël ^a,b,c,d,e   Gallea, Cecile ^a,b,c,d,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d CNRS   (France)

^e INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^f DIF   (France)

Author keywords

Diffusion imaging; Magnetization transfer; MRI; Parkinson's disease; Relaxometry; Resting state fMRI; Substantia nigra

Indexed keywords

NEUROMELANIN;

BRAIN CORTEX; BRAIN METABOLISM; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; FRACTIONAL ANISOTROPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOFREQUENCY; REVIEW; SUBSTANTIA NIGRA; TRACTOGRAPHY; VOXEL BASED MORPHOMETRY;

HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; RELAXATION; SUBSTANTIA NIGRA;

EID: 84862669321     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25015     Document Type: Review

References (73)

1. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999; 122: 1437-1448.
2. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991; 54: 388-396.
3. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
4. Beckstead RM, Domesick VB, Nauta WJ. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res. 1979; 175: 191-217.
5. Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat. 2003; 26: 317-330.
6. Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci. 2010; 11: 760-772.
7. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114: 2283-2301.
8. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318: 876-880.
9. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 2003; 26: 578-580.
10. Enochs WS, Petherick P, Bogdanova A, Mohr U, Weissleder R. Paramagnetic metal scavenging by melanin: MR imaging. Radiology. 1997; 204: 417-423.
11. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol. 2002; 23: 1747-1756.
12. Adachi M, Hosoya T, Haku T, Yamaguchi K, Kawanami T. Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. AJNR Am J Neuroradiol. 1999; 20: 1500-1506.
13. Hutchinson M, Raff U, Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM). Neuroimage. 2003; 20: 1899-1902.
14. Minati L, Grisoli M, Carella F, De Simone T, Bruzzone MG, Savoiardo M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol. 2007; 28: 309-313.
15. Pujol J, Junque C, Vendrell P, Grau JM, Capdevila A. Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arc Neurol. 1992; 49: 1119-1122.
16. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport. 2006; 17: 1215-1218.
17. Stern MB, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology. 1989; 39: 1524-1526.
18. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med. 1989; 10: 135-144.
19. Helms G, Draganski B, Frackowiak R, Ashburner J, Weiskopf N. Improved segmentation of deep brain grey matter structures using magnetization transfer (MT) parameter maps. Neuroimage. 2009; 47: 194-198.
20. Rademacher J, Engelbrecht V, Burgel U, Freund H, Zilles K. Measuring in vivo myelination of human white matter fiber tracts with magnetization transfer MR. Neuroimage. 1999; 9: 393-406.
21. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999; 46: 747-754.
22. Bazelon M, Fenichel GM, Randall J. Studies on neuromelanin. I. A melanin system in the human adult brainstem. Neurology. 1967; 17: 512-519.
23. Shibata E, Sasaki M, Tohyama K, et al. Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn Reson Med Sci. 2006; 5: 197-200.
24. Keren NI, Lozar CT, Harris KC, Morgan PS, Eckert MA. In vivo mapping of the human locus coeruleus. Neuroimage. 2009; 47: 1261-1267.
25. Hardy PA, Gash D, Yokel R, Andersen A, Ai Y, Zhang Z. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging. 2005; 21: 118-127.
26. Deoni SC, Rutt BK, Peters TM. Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med. 2003; 49: 515-526.
27. Deoni SC. High-resolution T1 mapping of the brain at 3T with driven equilibrium single pulse observation of T1 with high-speed incorporation of RF field inhomogeneities (DESPOT1-HIFI). J Magn Reson. Imaging 2007; 26: 1106-1111.
28. Menke RA, Jbabdi S, Miller KL, Matthews PM, Zarei M. Connectivity-based segmentation of the substantia Nigra in human and its implications in Parkinson's disease. Neuroimage. 2010; 52: 1175-1180.
29. Michaeli S, Grohn H, Grohn O, et al. Exchange-influenced T2rho contrast in human brain images measured with adiabatic radio frequency pulses. Magn Reson Med. 2005; 53: 823-829.
30. Michaeli S, Oz G, Sorce DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord. 2007; 22: 334-340.
31. Michaeli S, Sorce DJ, Springer CSJr, Ugurbil K, Garwood M. T1rho MRI contrast in the human brain: modulation of the longitudinal rotating frame relaxation shutter-speed during an adiabatic RF pulse. J Magn Reson. 2006; 181: 135-147.
32. Marrakchi-Kacem L, Delmaire C, Tucholka A, et al. Analysis of the striato-thalamo-cortical connectivity on the cortical surface to infer biomarkers of Huntington's disease. Med Image Comput Comput Assist Interv. 2011; 13: 217-224.
33. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999; 9: 179-194.
34. Lehericy S, Ducros M, Van de Moortele PF, et al. Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans. Ann Neurol. 2004; 55: 522-529.
35. Draganski B, Kherif F, Kloppel S, et al. Evidence for segregated and integrative connectivity patterns in the human Basal Ganglia. J Neurosci. 2008; 28: 7143-7152.
36. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage. 2000; 11: 805-821.
37. Makris N, Schlerf JE, Hodge SM, et al. MRI-based surface-assisted parcellation of human cerebellar cortex: an anatomically specified method with estimate of reliability. Neuroimage. 2005; 25: 1146-1160.
38. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999; 9: 195-207.
39. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nature Rev. 2003; 4: 469-480.
40. Basser PJ, Pajevic S, Pierpaoli C, Duda J, Aldroubi A. In vivo fiber tractography using DT-MRI data. Magn Reson Med. 2000; 44: 625-632.
41. Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol. 1999; 45: 265-269.
42. Poupon C, Clark CA, Frouin V, et al. Regularization of diffusion-based direction maps for the tracking of brain white matter fascicles. Neuroimage. 2000; 12: 184-195.
43. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage. 2009; 47: 435-441.
44. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Functional connectivity: the principal-component analysis of large (PET) data sets. J Cereb Blood Flow Metab. 1993; 13: 5-14.
45. Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995; 34: 537-541.
46. Honey CJ, Sporns O, Cammoun L, et al. Predicting human resting-state functional connectivity from structural connectivity. Proc Natl Acad Sci U S A. 2009; 106: 2035-2040.
47. Ramnani N, Behrens TE, Penny W, Matthews PM. New approaches for exploring anatomical and functional connectivity in the human brain. Biol Psychiatry. 2004; 56: 613-619.
48. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009; 10: 186-198.
49. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage. 2004; 21: 229-235.
50. Tambasco N, Belcastro V, Sarchielli P, et al. A magnetization transfer study of mild and advanced Parkinson's disease. Eur J Neurol. 2011; 18: 471-477.
51. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem. 1989; 52: 1830-1836.
52. *-weighted MRI at 3 Tesla. Magn Reson Med. 1994; 32: 335-341.
53. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology. 2008; 70: 1411-1417.
54. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain. 2010; 133: 3423-3433.
55. Seppi K, Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am. 2010; 20: 29-55.
56. Seppi K, Schocke MF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol. 2005; 18: 370-375.
57. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry. 2004; 75: 481-484.
58. Chan LL, Rumpel H, Yap K, et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78: 1383-1386.
59. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009; 72: 1378-1384.
60. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol. 2001; 8: 573-577.
61. Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord. 2002; 14: 64-76.
62. Choe BY, Park JW, Lee KS, et al. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invesi Radiol. 1998; 33: 450-455.
63. O'Neill J, Schuff N, Marks WJJr., Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord. 2002; 17: 917-927.
64. Baik HM, Choe BY, Son BC, et al. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy. Eur J Radiol. 2003; 47: 179-187.
65. Oz G, Terpstra M, Tkac I, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 Tesla: detection of high GABA concentrations. Magn Reson Med. 2006; 55: 296-301.
66. Helmich RC, Derikx LC, Bakker M, Scheeringa R, Bloem BR, Toni I. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cereb Cortex. 2009; 20: 1175-1186.
67. Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Toni I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol. 2011; 69: 269-281.
68. Rizzo G, Martinelli P, Manners D, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain. 2008; 131: 2690-2700.
69. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. 2006; 129: 1040-1049.
70. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004; 127: 791-800.
71. Karagulle Kendi AT, Lehericy S, Luciana M, Ugurbil K, Tuite P. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroadiol. 2008; 29: 501-505.
72. Draganski B, Ashburner J, Hutton C, et al. Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ). Neuroimage. 2011; 55: 1423-1434.
73. Kwon DH, Kim JM, Oh SH, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol. 2012; 71: 267-277.